Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report
Tóm tắt
Pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH) share an overlapping disease phenotype. Hence it is necessary to distinguish them. Our 14-year-old female patient admitted with progressive shortness of breath, dizziness, and fatigue even after minimal physical activity was clinically suspected for PAH, based on her previous history. Her chest computed tomography artery reported the presence of PVOD triad features - subpleural thickened septal lines, ground-glass nodules/opacities and mediastinal lymphadenopathy. Because of her weak physical stature, a lung biopsy was not performed; however, the genetic testing identified a novel heterozygous EIF2AK4 mutation at c.4833_4836dup (p.Q1613Kfs*10) - the dominant susceptible factor driving PVOD. Combination of genetic testing and computed tomography artery facilitated us to distinguish PVOD from PAH. Her disease symptoms advanced aggressively so that she died even before the lung transplantation, which was less than 6 months from the onset of disease symptoms. This case report highlights that novel EIF2AK4 mutation at [c.4833_4836dup (p.Q1613Kfs*10)] would predict an aggressive phenotype of PVOD. Hence, we conclude that a genetic test identifying EIF2AK4 mutation would serve as a tool for the early diagnosis of PVOD, circumventing lung biopsy.
Tài liệu tham khảo
Bal SK, Thangakunam B, Irodi A, Gupta M, Christopher DJ. Small sample lung biopsy findings in patients with Clinicoradiologic suspicion of pulmonary Venoocclusive disease-pulmonary capillary Hemangiomatosis. J Bronchology Interv Pulmonol. 2016;23(4):308–15.
Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmuller P, Preston SD, Southwood M, Hernandez-Sanchez J, Martin J, et al. Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation. 2017;136(21):2022–33.
Hajouli S, Moustafa MA, Memoli JSW. Pulmonary Veno-occlusive disease: a rare cause of pulmonary hypertension. J Investig Med High Impact Case Rep. 2019;7:2324709619840375.
Best DH, Sumner KL, Smith BP, Damjanovich-Colmenares K, Nakayama I, Brown LM, Ha Y, Paul E, Morris A, Jama MA, et al. EIF2AK4 mutations in patients diagnosed with pulmonary arterial hypertension. Chest. 2017;151(4):821–8.
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmuller P, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):65–9.
Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M. Thomas de Montpréville V, Girerd B, Jaïs X, Savale L et al: pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. J Heart Lung Transplant. 2018;37(5):647–55.
Tenorio J, Navas P, Barrios E, Fernández L, Nevado J, Quezada CA, López-Meseguer M, Arias P, Mena R, Lobo JL, et al. A founderEIF2AK4mutation causes an aggressive form of pulmonary arterial hypertension in Iberian gypsies. Clin Genet. 2015;88(6):579–83.
Montani D, Dorfmüller P, Girerd B, Le Pavec J, Fadel E, Simonneau G, Sitbon O. M. H: natural history over 8 years of pulmonary vascular disease in a patient carrying Biallelic EIF2AK4 mutations. Am J Respir Crit Care Med. 2018;198(4):537–41.
Liang L, Su H, Ma X, Zhang R. Good response to PAH-targeted drugs in a PVOD patient carrying Biallelic EIF2AK4 mutation. Respir Res. 2018;19(1):192.
Jiang X, Jing ZC. Epidemiology of pulmonary arterial hypertension. Curr Hypertens Rep. 2013;15(6):638–49.
Kumar P, Sinha SK, Pandey U, Thakur R, Varma CM, Sachan M, Goel A. Patent ductus arteriosus with Eisenmenger syndrome: difficult diagnosis made easily with saline contrast echocardiography. Cardiol Res. 2016;7(3):117–8.
Duarte AC, Cordeiro A, Loureiro MJ, Ferreira F. Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis. Clin Rheumatol. 2020;39(5):1687–91.
Montani D, Price LC, Dorfmuller P, Achouh L, Jais X, Yaici A, Sitbon O, Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease. Eur Respir J. 2009;33(1):189–200.
Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C, Rabiller A, Haque R, Sitbon O, Jais X, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine. 2008;87(4):220–33.
Ali N, Loughborough WW, Rodrigues JCL, Suntharalingam J, Hudson B, Hall T, Augustine D, Mackenzie R, Robinson G. Computed tomographic and clinical features of pulmonary veno-occlusive disease: raising the radiologist's awareness. Clin Radiol. 2019;74(9):655–62.
Ravishankar B, Liu H, Shinde R, Chaudhary K, Xiao W, Bradley J, Koritzinsky M, Madaio MP, McGaha TL. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc Natl Acad Sci U S A. 2015;112(34):10774–9.
Eichstaedt CA, Song J, Benjamin N, Harutyunova S, Fischer C, Grünig E. Hinderhofer K: EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension. Respir Res. 2016;17(1).
Padyana AK, Qiu H, Roll-Mecak A, Hinnebusch AG, Burley SK. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J Biol Chem. 2005;280(32):29289–99.
Zeng X, Lian T, Lin J, Li S, Zheng H, Cheng C, Ye J, Jing Z, Wang X, Huang W. Whole-exome sequencing improves genetic testing accuracy in pulmonary artery hypertension. Pulmon Circu. 2018;8(2):204589401876368.
Girerd B, Montani D, Jaïs X, Eyries M, Yaici A, Sztrymf B, Savale L, Parent F, Coulet F, Godinas L, et al. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J. 2016;47(2):541–52.
Doble B, Schofield D, Evans CA, Groza T, Mattick JS, Field M, Roscioli T. Impacts of genomics on the health and social costs of intellectual disability. J Med Genet. 2020. https://doi.org/10.1136/jmedgenet-2019-106445.